The LIGHT trial has been published in The Lancet.
This landmark trial, for which Prof Bourne was a site principal investigator, looks at treating glaucoma and ocular hypertension with Selective Laser Trabeculoplasty as an initial therapy instead of the standard treatment of eyedrop medications. Selective laser trabeculoplasty was associated with lower cost, good clinical outcomes, with lower symptom scores, and drop-freedom for most patients and should be offered as an alternative to intraocular pressure-lowering drops.